There were 617 press releases posted in the last 24 hours and 162,009 in the last 365 days.

Osteoarthritis Pharmaceutical and Healthcare Pipeline Review H2



Osteoarthritis Treatment Pipeline Review H2 2016

PUNE, INDIA, January 6, 2017 / -- GET SAMPLE REPORT @

Opportunity Analyzer: Osteoarthritis - Opportunity Analysis and Forecasts to 2024

Osteoarthritis (OA) is a slowly progressive joint disease that is typically seen in middle-aged to elderly people. The disease is caused by the breakdown of the joint cartilage due to mechanical stress or biochemical alterations, which causes the bone underneath to fail. OA can occur together with other types of arthritis, such as gout or rheumatoid arthritis (RA). OA tends to affect commonly used joints such as the hands and spine as well as the weight-bearing joints such as the hips and knees. The causes of OA are not fully understood. However, genetic factors, and damage to the joints, either through repeated excessive loading and stress of a joint over time (for example, the knee joint in an obese person) or by injury (such as a break or dislocation of a finger joint) increases the risk of developing OA. There is no single test to diagnose OA. Several methods are used to diagnose OA and to rule out other problems: medical history, physical exam, X-rays, blood tests, or joint fluid analysis. The structural changes that occur with old age may not be accompanied by symptoms, which makes the estimation of the prevalence of OA difficult.

- Overview of OA, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized OA therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the OA therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global OA therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Table of Contents
1 Table of Contents 10
1.1 List of Tables 14
1.2 List of Figures 18
2 Introduction 19
2.1 Catalyst 19
2.2 Related Reports 20
3 Disease Overview 21
3.1 Etiology and Pathophysiology 21
3.1.1 Etiology 21
3.1.2 Pathophysiology 24
3.2 Symptoms 26
4 Epidemiology 27
4.1 Disease Background 27
4.2 Risk Factors and Comorbidities 28
4.3 Global and Historical Trends 30
4.3.1 Total Prevalence of OA - 7MM 30
4.3.2 Diagnosed Prevalence of OA - 7MM 30
4.3.3 US 31
5 Current Treatment Options 90
5.1 Overview 90
5.2 Product Profiles - Major Therapies 92
5.2.1 NSAIDs (Numerous Branded and Generic Products) 92
5.2.2 Topical Therapies (Numerous Branded and Generic Products) 96
5.2.3 Opioids (Numerous Branded and Generic Products) 101
5.2.4 Antidepressants (Numerous Branded and Generic Products) 106
5.2.5 Intra-Articular Corticosteroid Injections (Numerous Branded and Generic Products) 108
6 Unmet Needs Assessment and Opportunity Analysis 112
6.1 Overview 112
6.2 Analgesic Drugs that Adequately Address Pain 113
6.3 Disease-Modifying Drugs 115
6.4 Drugs with Improved Tolerability for Use in the Elderly Patient Population 116
6.5 Improved Implementation of Guidelines on Non-pharmaceutical Treatments 117
7 Research and Development Strategies 121
7.1 Overview 121
7.2 Development of Pharmacological Treatments with Novel MOAs 121
7.3 Development of Disease-Modifying OA Drugs 122
7.4 Strategic Partnerships 123
7.5 Current Clinical Trial Design 124
8 Pipeline Assessment 129
8.1 Overview 129
8.2 Promising Drugs in Clinical Development 130
8.2.1 Ampion 130
8.2.2 NKTR-181 134
9 Pipeline Valuation Analysis 162
9.1 Clinical Benchmarking of Key Pipeline Drugs 162
9.2 Commercial Benchmark of Key Pipeline Drugs 163

Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here